Clinical trials: Chronic Liver Disease
Hepatitis B, Chronic
Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB
Tenofovir amibufenamide (TMF) is a novel prodrug of tenofovir that has been widely used in mainland China for the treatment of chronic hepatitis B (CHB).
- Trial name
- NCT06743438
- Testing
- Tenofovir Amibufenamide（TMF）
- Where
- China
- Volunteers
- 640 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Ascites Hepatic
"Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial"
This study aims to evaluate beneficial effects of using dapagliflozin in cirrhotic chronic liver disease patients. We hypnotized that the use of dapagliflozin will be associated with fewer need for large volume paracentesis hence…
- Trial name
- NCT07684326
- Testing
- Dapagliflozin
- Where
- Egypt
- Volunteers
- 52 people
- Sponsor
- Beni-Suef University
Liver Fibrosis
Prediction of Significant Liver Fibrosis
The deep learning method based on convolutional neural network (CNN) was used to extract the relevant features of liver fibrosis classification from the multi-modal information of digital pathological sections, clinical…
- Trial name
- PSLF (NCT06509230)
- Where
- China
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Huang Haijun
Hepatitis C Viral
Oral Microbiome of Patients With Hepatitis C Virus Infection
Hepatitis C virus (HCV) infection is very common in Egypt and the middle east. The disease affects multiple body organs and may proceed to hepatocellular carcinoma.
- Trial name
- NCT03682549
- Testing
- Oral microbiome analysis
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Cairo University
Growth Failure, Chronic Liver Disease
Increlex Treatment of Children With Chronic Liver Disease and Short Stature
A major consequence of chronic liver disease in childhood is growth failure. This is because a chemical essential for growth called growth factor is created in the liver.
- Trial name
- NCT01314508
- Testing
- Increlex
- Sponsor
- University of California, Los Angeles
Chronic Hepatitis C Virus
Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects
This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without ribavirin (RBV), administered for 8 or 12 weeks of treatment in…
- Trial name
- NCT01726517
- Testing
- LDV/SOF, RBV
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Gilead Sciences
Hepatitis B, Chronic
A Study to Assess DV-601 in Subjects With Chronic Hepatitis B
The purpose of this study is to determine if DV-601, an investigational, therapeutic vaccine will be well-tolerated and induce hepatitis B virus (HBV)-specific virological and immunological responses in chronic hepatitis B (CHB)…
- Trial name
- NCT01023230
- Testing
- DV-601, Entecavir
- Where
- 4 sites in Poland
- Volunteers
- 14 people
- Sponsor
- Dynavax Technologies Corporation
Hepatitis C, Chronic
Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)
The purpose of this study is to assess the efficacy of a short course of therapy (24 weeks) versus standard 48 week treatment in previously untreated adult participants with chronic hepatitis C (CHC) genotype 4 infection who…
- Trial name
- START 4 (NCT01606800)
- Testing
- PEG-IFN alfa-2b, ribavirin
- Volunteers
- 45 people
- Sponsor
- Merck Sharp & Dohme LLC
Thrombocytopenia, Hepatitis C
Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C
This study will provide chronic hepatitis C patients with low platelets (less than 75x10^9/L) the opportunity to undergo treatment and possible cure of their virus.
- Trial name
- SQUELCH-C (NCT01821625)
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Texas Southwestern Medical Center
Hepatitis C, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.
This single arm study will assess the efficacy and safety of PEGASYS in patients with chronic hepatitis C and end-stage renal disease, including patients on hemodialysis.
- Trial name
- NCT00474955
- Testing
- peginterferon alfa-2a [Pegasys]
- Where
- 5 sites in Russia
- Volunteers
- 27 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Liver Disease
Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients
This study will explore the relationship of different DEB025 doses in combination with RBV to pharmacokinetic, pharmacodynamic (i.e.
- Trial name
- NCT01970904
- Testing
- Alisporivir, Ribavirin, Peg-IFNα2a
- Where
- 25 sites in Germany, Poland and 2 more
- Volunteers
- 147 people
- Sponsor
- Debiopharm International SA
Hepatitis C
A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection
The purpose of this study is to determine whether a regimen consisting of daclatasvir and asunaprevir is effective in treatment-naive patients with chronic hepatitis genotype 1b infection.
- Trial name
- NCT02496078
- Testing
- Daclatasvir, Asunaprevir
- Where
- 29 sites in China, Russia and 1 more
- Volunteers
- 207 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis B, Viral Hepatitis
Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B
To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.
- Trial name
- NCT03933384
- Testing
- Tenofovir alafenamide, Entecavir
- Where
- Taiwan
- Volunteers
- 140 people
- Sponsor
- Taichung Veterans General Hospital
Hepatitis C, Chronic
SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.
This study will evaluate the efficacy and safety of 4 regimens of PEGASYS plus Copegus, in patients with chronic hepatitis C (CHC) genotype 1 who have failed to respond to previous treatment with standard doses of PEGASYS plus…
- Trial name
- NCT00412334
- Testing
- Copegus, peginterferon alfa-2a [Pegasys]
- Where
- 22 sites in France
- Volunteers
- 104 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) in hepatitis C virus (HCV)-infected adults who are undergoing…
- Trial name
- NCT02728206
- Testing
- SOF/VEL
- Where
- New Zealand
- Volunteers
- 9 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
This open-label, multi-center study will evaluate the safety and tolerability and the effect on viral activity of a combined PEGASYS and COPEGUS extended therapy in patients with chronic hepatitis C with genotype 1, 2 and 3.
- Trial name
- NCT01033448
- Testing
- COPEGUS, peginterferon alfa-2a [Pegasys]
- Where
- 20 sites in Israel
- Volunteers
- 59 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis b
Prevalence of Occult Hepatitis B Virus Infection（OBI） in Subjects With Chronic Hepatitis B（CHB） Family History
Mother to Child transmission is the main route of hepatitis B virus (HBV) transmission in China, attributing to over 50% HBV infection.
- Trial name
- NCT04672915
- Testing
- test of HBV DNA
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Chronic Hepatitis C
Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis C Infection
Phase I/II trial of KRN7000 in patients with chronic hepatitis C. Study objectives: To evaluate and compare the safety and tolerability of 3 ascending doses of a-GalCer.
- Trial name
- NCT00352235
- Testing
- KRN7000
- Where
- Netherlands
- Volunteers
- 36 people
- Sponsor
- Foundation for Liver Research
Thrombocytopenia Associated With Chronic Liver Disease
A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
The main aim of this clinical trial is to assess the safety and efficacy of a single dose of PN20 in treatment of thrombocytopenia in adult patients with chronic liver disease undergoing an elective procedure.
- Trial name
- NCT07446491
- Testing
- PN20
- Where
- 8 sites in China
- Volunteers
- 54 people
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
End Stage Liver Disease, End Stage Renal Disease
Transplant and Addiction Project (TAP) - 1
The purpose of this study is to test a novel distance-based (telephone) intervention to help transplant candidates with current or recent substance abuse to stay "clean and sober" both prior and following transplant surgery.
- Conditions
- End Stage Liver Disease, End Stage Renal Disease, Substance-Related Disorders
- Trial name
- NCT00249652
- Testing
- TAP, TAU
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- St. Luke's-Roosevelt Hospital Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.